Cargando…

Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial

We report results of a phase 2, randomized, multicenter, open‐label, two‐arm study evaluating the safety and efficacy of eculizumab in preventing acute antibody‐mediated rejection (AMR) in sensitized recipients of living‐donor kidney transplants requiring pretransplant desensitization (NCT01399593)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Marks, William H., Mamode, Nizam, Montgomery, Robert A., Stegall, Mark D., Ratner, Lloyd E., Cornell, Lynn D., Rowshani, Ajda T., Colvin, Robert B., Dain, Bradley, Boice, Judith A., Glotz, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790671/ https://www.ncbi.nlm.nih.gov/pubmed/30887675 http://dx.doi.org/10.1111/ajt.15364

Ejemplares similares

Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies
por: Glotz, Denis, et al.
Publicado: (2019)

Desensitization protocol enabling pediatric crossmatch-positive renal transplantation: successful HLA-antibody-incompatible renal transplantation of two highly sensitized children
por: Adamusiak, Anna M., et al.
Publicado: (2016)

Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients
por: Fernández Rivera, Constantino, et al.
Publicado: (2022)

Current Approaches to Desensitization in Solid Organ Transplantation
por: Schinstock, Carrie, et al.
Publicado: (2021)

The use of eculizumab as a bridge to retransplantation for chronic antibody-mediated rejection in a heart transplant recipient: a case report
por: Kearney, Katherine, et al.
Publicado: (2021)

Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies
por: Kim, Jon Jin, et al.
Publicado: (2017)

Can pre-implantation biopsies predict renal allograft function in pediatric renal transplant recipients?
por: Kari, Jameela A., et al.
Publicado: (2015)

Long-term Use of Eculizumab in Kidney Transplant Recipients
por: Milan Manani, Sabrina, et al.
Publicado: (2018)

The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials
por: Haas, M., et al.
Publicado: (2018)

A Kidney Transplant Recipient on Prophylactic Eculizumab Presenting With Myalgia
por: Shivakumar, Oshini, et al.
Publicado: (2022)

Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature
por: Tran, Duy, et al.
Publicado: (2016)

Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation
por: Yerly, Patrick, et al.
Publicado: (2022)

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Utilisation of small paediatric donor kidneys for transplantation
por: Damji, Samir, et al.
Publicado: (2018)

Clinical Outcomes of Perioperative Desensitization in Heart Transplant Recipients
por: Plazak, Michael E., et al.
Publicado: (2021)

Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice
por: Lin, Jiaxin, et al.
Publicado: (2020)

Alloimmune Risk Stratification for Kidney Transplant Rejection
por: Bestard, Oriol, et al.
Publicado: (2022)

Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
por: Durán, Carlos E., et al.
Publicado: (2012)

Endothelial failure and rejection in recipients of corneas from the same donor
por: Downward, Lewis, et al.
Publicado: (2022)

CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection
por: van den Bosch, Thierry P. P., et al.
Publicado: (2017)

Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS
por: Favi, Evaldo, et al.
Publicado: (2022)

The Role of the Endothelium during Antibody-Mediated Rejection: From Victim to Accomplice
por: Cross, Amy Rachael, et al.
Publicado: (2018)

THE EFFECT OF SKIN HOMOGRAFT REJECTION ON RECIPIENT AND DONOR MIXED LEUKOCYTE CULTURES
por: Oppenheim, Joost J., et al.
Publicado: (1965)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
por: Jordan, Stanley C., et al.
Publicado: (2021)

Use of a Sulfa Desensitization Protocol in Solid Organ Transplant Recipients
por: Kirsch, Denise, et al.
Publicado: (2017)

Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
por: Toyoda, Mieko, et al.
Publicado: (2017)

Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study
por: Shaffer, David, et al.
Publicado: (2016)

The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody‐mediated rejection
por: Loupy, Alexandre, et al.
Publicado: (2020)

Predictive Potential of Flow Cytometry Crossmatching in Deceased Donor Kidney Transplant Recipients Subjected to Peritransplant Desensitization
por: Osickova, Klara, et al.
Publicado: (2021)

Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients
por: Morrison, Alexander H., et al.
Publicado: (2019)

Eculizumab Dosing in Infants
por: Kobrzynski, M., et al.
Publicado: (2018)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey
por: Akamatsu, Nobuhisa, et al.
Publicado: (2021)

A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy
por: Guo, Zhiliang, et al.
Publicado: (2023)

636. Meningococcal Vaccination and Antibiotic Prophylaxis Practices in Solid Organ Transplant Recipients undergoing Eculizumab Therapy
por: Bhaimia, Eric, et al.
Publicado: (2022)

Histopathologic Features of Antibody Mediated Rejection: The Banff Classification and Beyond
por: Cornell, Lynn D.
Publicado: (2021)

The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018)

Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter
por: Plasse, Richard A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o1fl1uivprm4fenmdvn5uol484